Excerpts

NR, HR 0.29 CI 95% 0.10–0.86, p = 0.02) and a trend towards significance in PFS (5.0 vs. 14.2 months, HR 0.43, CI 95% 0.15–1.25, p = 0.12) ( Figure 1 e).

Subgroup analysis of patients ≥60 years showed a trend toward improved 2-year OS with fludarabine/cyclophosphamide/total body irradiation (Flu/Cy/TBI) versus fludarabine/busulfan: 71% versus 53% (HR = 0.47, p = 0.121).

Cases with MSI had a lower DFS ( p = 0.036), and showed a trend towards poorer OS ( p = 0.129) ( Figure 2 E,F). 3.

Progression-Free Survival Patients with high pathological necrosis (≥80%) showed a nonsignificant trend toward improved PFS compared with those with poor necrosis ( p = 0.13).

In this independent dataset, patients with double mutations affecting both TP53 / SMAD4 and TP53 / FBXW7 showed a trend towards reduced OS rates at the multivariable setting ( p = 0.13 and p = 0.096, respectively) ( Table S4; Figure S5A,B ).

KGR for segments 2+3 has a tendency toward statistical significance (LVD 1.891, eLVD 2.886 versus PVE 1.724, p = 0.1309).

Convexity meningiomas showed a trend toward lower odds of preoperative seizures (OR = 0.179; p = 0.132), although this was not statistically significant.

However, the expression level one of the measured miRNAs, miR378c, showed a nonsignificant trend toward upregulation in response to treatment ( p = 0.138) ( Figure 2 A).

In regions with low VEGFR2 expression, this difference was not significant but again showed a trend toward higher expression in HPV-negative tumors ( Figure 3 A; p = 0.140).

37.8 months in the validation cohort, p = 0.006), highlighting a slight trend in the PFS in a multivariate analysis of erlotinib-treated patients (PFS 11.0 vs. 15.0 months, p = 0.14) [ 111 ].

Smoking history showed a trend toward increased recurrence risk with a HR of 1.61 (95% CI 0.85–3.04, p = 0.14), though this did not reach statistical significance.

Patients with higher score of the immune response module IMMUNE1 showed no significant tamoxifen benefit (HR (95% CI) = 0.67 (0.34–1.33)), whereas patients with low IMMUNE1 score did (HR (95% CI) = 0.35 (0.20–0.61)) with borderline significant interaction test in univariate ( p = 0.14) and multivariable analyses ( p = 0.09) ( Figure 6 E,F).

CEUS to absolute dose applied (per cycle 1; Supplementary Tables S2 and S4 ) showed a trend (correlation coefficient r = 0.498, p = 0.142), and DCE-MRI VVF measurements showed a significant correlation with absolute dose applied per cycle 1 (r = 0.556, p = 0.038) but not with dose level per m 2 , whereas k-trans measurements only showed trends.

1.0 ± 0.2, p = 0.046), and SDHA expression showed a trend for higher expression (2.5 ± 0.6 vs. 1.6 ± 0.3, p = 0.144). 3.6.

G415 cells also showed a trend of reduction in their invasion ability ( p = 0.14466, by t -test) ( Figure 5 b right).

MET overexpression showed a trend toward improved PFS (HR: 0.77, 95% CI: 0.54–1.09, p = 0.145) ( Figure 3 A).

Further analysis of the tumor IHC staining which compared c-myc staining at the invasive front to the inner layer also showed a trend for reduced c-myc expression, with the strongest trend at the invasive front ( p = 0.1465) ( Figure S2A ). 2.2.

The five TPM cases showed a trend ( p = 0.149) for decreased/absent HDAC9 expression in the nucleus of pNEN cells.

All the factors showing a marginally significant association with OS ( p < 0.15) in the univariate analysis were entered into a stepwise Cox regression analysis, with significant variables selected by the stepwise method.

The 3-, 4-, and 5-year radiomics-based OS stratifications were significant in the HPV-associated cohort ( p = 0.001, p = 0.02, and p = 0.02, respectively), while the 2-year OS p -value approached significance ( p = 0.15; Figure 3 b).

With 233 patients recruited, SBRT showed a trend towards improved local control (LC) compared to HRT (87.6% vs. 81.2%), but the trial was underpowered to confirm this ( p = 0.15).

Interestingly, the proteomics data also indicated that T235 exhibited an approximately twofold decrease in SPRY4 expression upon co-culture with macrophages, although only moderately significant ( p < 0.15), which was supported by Western blot analysis. 3.8.

Thus, among the 12 SNPs genotyped or imputed in this study from 26 GC susceptibility markers in previous GWASs [ 19 , 20 , 21 , 22 , 23 , 24 ], half with a marginally significant relationship with GC ( p -value < 0.15) were considered for the PRS.

Among the thirteen lncRNAs, ENST00000671612.1 correlated with worse refractory free survival (RFS); p value = 0.01; and HR = 2.0 (1.1–3.7), as presented in Figure 10 a,b, while ENST00000520619.1 exhibited marginal significance in predicting RFS ( p = 0.15, supplementary Figure S1 ).

CPS 10–49 showed a trend toward shorter survival compared to CPS ≥50 (HR, 2.28; 95% CI, 0.74–7.00; p = 0.152), although this difference was not statistically significant, possibly due to the limited sample size. 3.6.